ERNA Eterna Therapeutics, Inc.: Net earnings per one share for the last twelve months

Public company logo of Eterna Therapeutics (ERNA)

The blood cancer treatment sector relies on securing venture capital for clinical trials. Eterna Therapeutics (ERNA) utilizes mRNA and CRISPR for precise cell programming, ensuring macro-resilient demand regardless of GDP. The TTM annual net income per share dynamics reflect current trends, where the value of 86.00 characterizes this level of operational momentum.

Eterna Therapeutics, Inc. (ERNA): Net earnings per share (EPS TTM) from 02/11/2024 to 11/18/2026

Financial and market metric breakdowns for Eterna Therapeutics Inc (ERNA)

- share price and expert price forecast:
Fundamental company valuation:ERNA, Eterna Therapeutics Inc
Core merchandise of Eterna Therapeutics, Inc.

The continuity of component supplies for cell engineering at Eterna Therapeutics (ERNA) directly impacts operational efficiency. The twelve-month earnings per share (EPS) trend aggregates these costs, reflecting the actual growth rate of net yield. This metric compares current earnings with the previous period to assess capital efficiency. It is critical for investors to correlate this growth with resource costs. By analyzing the rolling annual EPS change, one can identify the resilience of the business model.